Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Nov 2018;114:26-28
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, Phase 2 trial conducted in the USA
Variations in detoxification genes (GCLC, GST) may affect endogenous glutathione production
Inhibition of NMT by IMP-366 has been shown to induce apoptosis in cancer cell lines by impacting the global myristoylation of lymphoma cell proteins (Kallemeijn et al
Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive
Her husband, Alexis Ohanian, is an investor in Ro and serves on its board
